All diseases

Disease Atlas / Disease detail

Progressive supranuclear palsy

An atlas of 4R-tau atypical parkinsonism, early falls, eye-movement, cognitive and swallowing problems, and symptomatic care.

progressive supranuclear palsy · PSP · Steele-Richardson-Olszewski syndrome

MONDO:0019037Public QA completeSource-bound · 4

Disease at a glance

Start with the essentials, then explore the patient and research views.

Public revision · 9b98086d2cf3

Disease class
PSP is a progressive neurodegenerative disorder.
Core mechanism
Abnormal 4R-tau accumulation is characteristic.
Genes or cause
Early imbalance and backward falls are common.
Typical features
Slow or restricted vertical eye movements are characteristic.
Variability
Axial rigidity, gait freezing, and speech change occur.
Diagnosis
Swallowing, cognitive, and behavioral problems can progress.
Management
Diagnosis is clinical without a single confirmatory test.
Treatment and research
MRI and testing help exclude mimics.
Reading evidence
Levodopa response may be limited.
Key caution
Fall prevention and walking aids are introduced early.

For patients and families

A structured guide for understanding the disease and preparing for clinical conversations.

At a glance

PSP is a progressive neurodegenerative disorder.

Slow or restricted vertical eye movements are characteristic.

How the disease works

Abnormal 4R-tau accumulation is characteristic.

Early imbalance and backward falls are common.

Why experiences vary

Axial rigidity, gait freezing, and speech change occur.

Diagnosis and management

Swallowing, cognitive, and behavioral problems can progress.

Treatment status

Diagnosis is clinical without a single confirmatory test.

MRI and testing help exclude mimics.

Reading clinical trials

Multidisciplinary, palliative, and care planning begins early.

Topics for a clinical visit

Falls, eye movement, swallowing, and care goals require review.

Medical notice

This material is for disease education and is not a personal diagnosis or treatment instruction.

Evidence and sources

A trial registry status does not establish efficacy or regulatory approval.